Breast Cancer: Update Bulletin #3

Date: February 1, 2018
Price:
US$ 1,095.00
License [?]:
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B2FC27DC39DEN
Leaflet:

Download PDF Leaflet

Breast Cancer: Update Bulletin #3
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza (olaparib; AstraZeneca) for patients with metastatic BC with BRCA gene mutation; Pfizer’s talazoparib EMBRACA Phase III data in patients with advanced or metastatic BC; as well as Syndax Pharmaceuticals announcing a collaboration with Genentech for a Phase Ib/II trial evaluating the combination of entinostat with Tecentriq (atezolizumab) in patients with second-line HR+/HER2- metastatic BC.

Business Questions:
  • How do KOLs view Lynparza’s approval?
  • What do KOLs consider Lynparza’s advantages/disadvantages?
  • According to KOLs, how will Lynparza be positioned?
  • How does talazoparib’s safety/efficacy compare to Lynparza?
  • Does talazoparib have any advantages over Lynparza?
  • What do KOLs think of combining entinostat with Tecentriq (atezolizumab)?
  • Which entinostat combination trial holds the most promise? Why?
Skip to top


Ask Your Question

Breast Cancer: Update Bulletin #3
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: